GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
Z

Zhaoke Ophthalmology 6622.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

2.09

-0.48%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Zhaoke Ophthalmology

Its shares trade on HKEX under the ticker 6622.HK. It has been listed since 29 April 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥36.3m and a net loss of CN¥237.4m. At that date it held total assets of CN¥2.26bn and shareholders' equity of CN¥1.84bn.

Zhaoke Ophthalmology Ltd. operates as holding company with interest in providing ophthalmic pharmaceuticals. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2021-04-29. The Company’s products include innovative drugs and generic drugs. The firm ‘s products are mainly applied in five ophthalmic indications, including dry eye disease (DED), wet age-related macular degeneration (wAMD), diabetic macular edema (DME), myopia and glaucoma.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
29 Apr 2021
Employees
321
Website
zkoph.com ↗

Leadership

Pay as last reported

  • Dr. Xiaoyi LiExecutive Chairman, Chief Executive Officer, since 2017CN¥39.0m
  • Dr. Lit Fui LauPresident, Chief Operating Officer, Chief Scientific Officer
  • Ms. Xinyan FengChief Financial Officer
  • Dr. Lok Yee LiSenior Vice President - Research and Development
  • Ms. Lei YangGeneral Counsel
  • Ms. Suk Yan YauFinancial Controller, Company Secretary
  • Mr. Guohui ZhangDeputy General Director
  • Mr. Xiangrong DaiExecutive Director, since 2020CN¥514,000
  • Mr. Jiang FengDirector of Sales, Director of Marketing
  • Mr. Mauro BoveBusiness Development Director
  • Mr. Su JiangClinical Operations Director
  • Dr. Yixuan JinAssociate Medical Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Operates as a holding company with interest in ophthalmic pharmaceuticals
  • Headquartered in Guangzhou, Guangdong with 321 full-time employees
  • Offers innovative and generic drugs for five ophthalmic indications

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on competitive advantages or unique technologies

Opportunities

  • Expansion of innovative drug portfolio in ophthalmic treatments
  • Growth potential in dry eye disease, wet AMD, DME, myopia, and glaucoma markets
  • Potential for increased market share post-IPO in 2021

Threats

  • No specific threats mentioned in the provided information
  • No details on regulatory challenges or competition in the pharmaceutical sector
  • No information on potential market saturation or economic downturns

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.